Genmab
Pharmaceutical Company
Genmab to cut 130 jobs in Brooklyn Park, sell biotech factory...high-tech facility it bought less than two years ago. Genmab, based in Copenhagen, announced that it was closing the plant it bought from PDL Biopharma for $240 million in February 2008. In a conference call with analysts, company CEO Lisa... In this article: Genmab, Head and neck cancer, Denmark, Minneapolis, St. Paul, Copenhagen, and United Kingdom |
-
Prime Newswire | November 10, 2009
Genmab Announces Results for the Nine Months Period of 2009
...Results for the Nine Months Period of 2009 COPENHAGEN, Denmark, Nov. 10, 2009 (GLOBE NEWSWIRE) -- Summary: Genmab reports results for the nine month period ended September 30, 2009. Genmab A/S (Copenhagen:GEN) announced today results...
In this article: Genmab A/S, GlaxoSmithKline, Revenue, Ofatumumab, FDA, Zalutumumab, NHL, Trademark, Rituximab, and US
-
Genmab Announces Start of Ofatumumab Phase III Head to Head Study in DLBCL
Genmab Announces Start of Ofatumumab Phase III Head to Head Study in DLBCL COPENHAGEN, Denmark, Nov. 9, 2009 (GLOBE NEWSWIRE) -- Summary: Genmab has initiated a Phase III study of Arzerra ofatumumab in diffuse large B-cell lymphoma. Genmab...
In this article: Ofatumumab, Rituximab, Trademark, GlaxoSmithKline, Cancer, and B-cell lymphoma
-
Genmab Revises Financial Guidance
...on the financial impact of the reorganization plan announced today. Genmab A/S (Copenhagen:GEN) announced today it is revising its 2009 financial guidance. Genmab announced a reorganization plan in a separate stock exchange release...
In this article: Genmab A/S, Revenue, Trademark, GlaxoSmithKline, Cancer, Ofatumumab, and USA
-
Genmab Reorganizes to Build Sustainable Business
COPENHAGEN, Denmark, Nov. 5, 2009 (GLOBE NEWSWIRE) -- Summary: Genmab is planning to reorganize to match resources to ongoing and future needs, sell its U.S. manufacturing facility and reduce headcount by approximately 300 positions.
In this article: Trademark, Cancer, Head and neck cancer, Zalutumumab, GlaxoSmithKline, and U.S.
-
Genmab Achieves Milestone in Arzerra Collaboration
Genmab Achieves Milestone in Arzerra Collaboration COPENHAGEN, Denmark, Oct. 26, 2009 (GLOBE NEWSWIRE) -- Summary: Genmab will receive a milestone payment of approximately DKK 116million from GSK for the FDA approval of Arzerra for the...
In this article: GlaxoSmithKline, Trademark, Fludarabine, Alemtuzumab, FDA, Cancer, and Ofatumumab
-
GSK and Genmab Receive Accelerated Approval for Arzerra
GSK and Genmab Receive Accelerated Approval for Arzerra COPENHAGEN, Denmark and PHILADELPHIA, Oct. 26, 2009 (GLOBE NEWSWIRE) -- Summary: GSK and Genmab have received approval of Arzerra (ofatumumab) from the FDA for CLL that is refractory to...
In this article: GlaxoSmithKline, Fludarabine, Cancer, Alemtuzumab, FDA, Trademark, Ofatumumab, and Safe harbor
Trends
Loading...
More on Genmab
Description from Wikipedia:
Genmab A/S () is a Danish pharmaceutical company, founded in February 1999 and based in Copenhagen. Internationally, it operates through the subsidiaries Genmab BV in Utrecht, The Netherlands, Genmab Ltd in Stevenage, United Kingdom Genmab, Inc in Princeton, New Jersey, USA, and is publicly traded on the OMX Nordic Exchange and the OMX Copenhagen 20. Genmab, Inc recently expanded with an antibody manufacturing facility in Brooklyn Park, Minnesota, USA.
- Name:
- Genmab A/S
- Type:
- Public ()
- Location:
- Copenhagen, Denmark
- Founded:
- 1999
- Industry:
- Biotechnology
- Key People:
- Lisa Drakeman , Michael Widmer
- Products:
- Pharmaceuticals, antibodies
- Revenue:
- DKK 745.1 million
- No. of Employees:
- 550
Explore everything named Genmab...
